Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines

European Journal of Pharmacology

Volumn 474, Issue 2-3, 2003, Pages 137-140

  Neumeyer, John L ^a,b,c,d   Kula, Nora S ^a,b   Bergman, Jack ^a,b,c   Baldessarini, Ross J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Mailman Research Center   (United States)

^c Brain Research Laboratories Inc   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Dopamine; Dopamine D1 receptor; Partial agonist; Phenylbenzazepine

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADRENERGIC RECEPTOR; BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; MCL 201; MCL 202; MCL 203; MCL 204; MCL 205; MCL 206; MCL 207; MCL 209; MCL 210; MCL 211; MCL 212; MCL 213; MCL 214; MCL 215; MCL 216; MCL 217; MCL 218; MCL 230A; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENETIC TRANSFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0142102387     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02008-9     Document Type: Article

References (17)

1. Bergman J., Goldberg S.R. Attenuation of cocaine self-administration in monkeys by the dopamine D1 agonist SKF-83959. NIDA Res. Monogr. 179:1998;318.
2. Bergman J., France C.P., Holtzman S.G., Katz J.L., Koek W., Stephens D.N. Agonist efficacy, drug dependence, and medication development: preclinical evaluation of opioid dopaminergic, and GABA-A-ergic ligands. Psychopharmacology. 153:2000;67-84.
3. 3H]SCH-23390, a ligand selective for D1 dopamine receptor sites, in rat brain tissue. Biochem. Pharmacol. 38:1989;473-480.
4. Karlsson P., Smith L., Farde L., Harnryd C., Sedvall G., Wiesel F.A. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH-39166 on acutely ill schizophrenic patients. Psychopharmacology. 121:1995;309-316.
5. Khroyan T.V., Barrett-Larimore R.L., Rowlett J.K., Spealman R.D. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J. Pharmacol. Exp. Ther. 294:2000;680-687.
6. Kula N.S., George T., Baldessarini R.J. Rate of recovery of D1 and D2 dopaminergic receptors in young vs. adult rat striatal tissue following alkylation with ethoxycarbonylethoxy-dihydroquinoline (EEDQ). Dev. Brain Res. 66:1992;286-289.
7. Kula N.S., Baldessarini R.J., Kebabian J.W., Neumeyer J.L. S(+)-aporphines are not selective for human D2 dopamine receptors. Cell. Mol. Neurobiol. 14:1994;185-189.
8. Kula N.S., Baldessarini R.J., Kebabian J.W., Bakthavachalam V., Xu L. RBI-257: a highly potent D4-selective dopamine receptor ligand. Eur. J. Pharmacol. 331:1997;333-336.
9. 3H]ligand for serotonin-2 receptor binding sites. Mol. Pharmacol. 21:1982;301-314.
10. Mathur V.S. The role of the D1A receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev. Cardiovasc. Med. 14(Suppl. 1):2003;35-40.
11. 1 dopamine receptor: synthesis and characterization of R(+) and S(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5- tetrahydro-1H-3-benzazepine and its 6-bromo analog. J. Med. Chem. 35:1992;1466-1471.
12. Neumeyer J.L., Booth R.G., Baldessarini R.J. Therapeutic and diagnostic agents for Parkinson's disease. Abraham D. Burger's Medicinal Chemistry and Drug Discovery. 6th ed. 2003;711-741 Wiley, New York. Chap. 12 in Vol. 5.
13. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;Humana Press, Totowa, NJ.
14. Pettibone D.J., Flagg S.D., Totaro J.A., Clineschmidt B.V., Huff J.R., Young S.D., Chen R. A new high-affinity selective radioligand for brain α2 adrenoceptors. Life Sci. 44:1989;459-467.
15. Platt D.M., Rowlett J.K., Spealman R.D. Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF-83959 and SKF-77434. J. Pharmacol. Exp. Ther. 293:2000;1017-1026.
16. Rosenzweig-Lipson S., Bergman J. Induction of catalepsy-associated behavior by dopamine D1 partial agonists in squirrel monkeys. Eur. J. Pharmacol. 260:1994;237-241.
17. Singh N.K., Goyal R.K. New classes of antihypertensive drugs: therapeutic potentials. Clin. Exp. Hypertens. 21:1999;137-143.